Panelists discuss novel antibody-drug conjugates targeting CD30, CD19, CD22, and CD79B that are being explored as treatments for patients with lymphoid malignancies.
For more from this discussion, visit [ Ссылка ]
Ещё видео!
Panelists discuss novel antibody-drug conjugates targeting CD30, CD19, CD22, and CD79B that are being explored as treatments for patients with lymphoid malignancies.
For more from this discussion, visit [ Ссылка ]